Biomarker Focus TAmiRNA specializes in microRNA and RNAi-based biomarkers with a minimal-invasive approach, presenting clear cross-sell opportunities to diagnostic labs, pharma partners, and translational research programs seeking non-invasive disease markers in musculoskeletal, cardiovascular, and metabolic diseases.

Clinical Collaboration Recent partnerships and university collaborations, including with the Medical University of Vienna on hepatomiR and active participation in RNA therapeutics forums, indicate openness to joint development projects and contract research for biomarker discovery and validation.

Expansion Opportunities Product launches such as the miND workflow and lyophilized miND spike-in kit demonstrate a move toward scalable, field-ready solutions, enabling sales discussions around UDI-friendly, kits for end-to-end small RNA sequencing quality control and discovery.

EV Transcriptomics TAmiRNA’s emphasis on extracellular vesicle transcriptomics positions them to offer services or partnerships around EV-derived biomarkers, attracting biotech and pharma customers pursuing non-invasive diagnostic and monitoring tools.

Strategic Events Active presence at RNA Leaders Europe, ISEV, GSEV, and Precision Medicine EV Forum signals opportunity to engage prospects at industry conferences, supporting lead generation and targeted outreach to researchers, CROs, and potential enterprise clients.